Since the initial US Food and Drug Administration (FDA) approval of Kymriah in 2017, interest in cell therapies has exploded, with seven cell therapies on the market and over 2,800 in development. This rapid growth holds immense promise for patients, but conventional contract development and manufacturing organizations (CDMOs) are unable to meet the excessive patient demand for these life-saving cell therapies. As a result, patients are dying on the waitlist even though they are eligible for FDA-approved cell therapies.
In this webinar, the expert speaker will introduce a novel approach to the mass manufacturing of personalized living drugs. Cellares’ global network of smart factories can produce ten times more cell therapy batches per year than conventional CDMO facilities. This productivity jump is enabled by Cellares’ Cell Shuttle manufacturing platform, which reduces labor and facility size by 90 percent.
Register for this webinar today to gain insights into a novel approach that can be useful for large-scale cell therapy manufacturing.
Keywords: Manufacturing, Cell Therapy, Commercial Manufacturing, ATMPs, Biologics Manufacturing, Cell and Gene Therapy, Cell & Gene Therapies, CDMO/CMO, CGT
